Understanding Thyroid eye disease
TED often accompanies Graves disease but can occur when thyroid hormone levels are normal or low. Treating thyroid function is important, yet normal blood results do not prove the eye disease is inactive or that double vision has resolved. [1]
Activity describes inflammation; severity describes functional impact and threatened structures. An eye can have substantial persistent misalignment or proptosis after obvious redness settles. This distinction helps clinicians discuss medical treatment, surgery and support without dismissing chronic symptoms. [3]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Dry, exposed or uncomfortable eyes
Lid retraction and incomplete closure can expose the surface, causing irritation, watering, light sensitivity or blur. Discomfort and visible changes can interfere with daily life even without optic neuropathy. [2]
Binocular double vision
Swollen or scarred eye muscles may restrict movement and misalign the eyes. Image separation can change with gaze, making reading, stairs or driving more difficult. [1]
Changes in sight or appearance
Proptosis and lid changes can affect appearance and wellbeing. A smaller subset develops optic-nerve dysfunction with reduced acuity, color or field; the amount of bulging alone does not measure nerve safety. [1] [3]
Three different orbital consequences
Original mechanism comparison, not a severity scale or a promise that the depicted sequence occurs. [1] [2] [3]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Surface exposure
Lid position can impair eye-surface protection.
- Movement restriction
Muscle swelling or scarring can misalign the eyes.
- Optic-nerve crowding
Some cases threaten nerve function and need urgent assessment.
What is happening—and what remains uncertain
Immune activity in orbital tissues can enlarge muscles and fat and alter their function. Inflammation and later tissue remodeling can contribute differently to symptoms, so an “active/inactive” label is not a complete description of the person’s needs. [3]
Several mechanisms may impair vision: an exposed cornea, misalignment producing diplopia, or crowding around the optic nerve. These require different measurements and treatment goals. A simulation of two images does not show orbital pressure or corneal integrity. [1] [2]
What can look similar?
Thyroid function versus eye activity
Thyroid hormone abnormalities and orbital disease are related but not identical. Eye findings need assessment even when thyroid control is good. [1]
Restrictive versus nerve-related diplopia
TED can restrict eye-muscle movement. Cranial nerve palsy or ocular myasthenia can also cause double vision through different mechanisms and may need investigation in an atypical presentation. [3]
Other orbital disease
Markedly asymmetric or atypical findings can prompt imaging for other orbital causes. Not every enlarged muscle or protruding eye is TED. [3]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Check threatened sight firstAcuity, color, pupils, field and corneal examination help assess optic-nerve and exposure concerns. These are distinct from a cosmetic assessment or an inflammation score alone. [3]
- Measure alignment and orbital changeClinicians assess movements, diplopia, lids and proptosis and document change over time. Imaging is selected for diagnostic uncertainty, suspected compression or treatment planning. [3]
- Include thyroid status and treatment safetyThyroid testing and overall health inform care. Before selected biologic therapies, hearing, glucose, bowel disease and reproductive considerations may affect the benefit–risk discussion and monitoring. [4] [5]
What may help—and what is still being studied
Support the surface and thyroid health
Clinicians may recommend surface protection and coordinated thyroid management. Smoking cessation support is relevant when applicable; it should be offered without blame. Avoid self-prescribing selenium or changing thyroid medicines from an online guide. [2] [3]
Choose treatment for the actual problem
Inflammation-directed therapy, biologics, radiation or surgery have different roles. Sight-threatening optic neuropathy or corneal breakdown follows an urgent specialist pathway; stable alignment or lid problems may be addressed differently. [3]
Use current evidence and local access
US-approved IGF-1R therapies include teprotumumab and, since June 26, 2026, veligrotug. Availability and approvals elsewhere differ. Both labels include hearing, glucose, bowel and infusion warnings; an approved indication is not proof one drug is best for every person or an emergency nerve-compression substitute. The current teprotumumab label also warns about encephalopathy: new confusion or other suggestive neurological symptoms need immediate medical attention and clinician-directed evaluation, not independent dose changes. [4] [5] [6]
What this can mean for daily life
Make reading comfortable
Adjust text size, lighting and screen position. An eye professional can advise on surface care and whether a temporary prism or other diplopia aid is suitable. [1] [2]
Discuss transport and navigation
Double vision and field loss may affect driving and stairs. Agree a safe transport and work plan rather than assuming a normal chart result establishes readiness. [3] [8]
Address appearance and wellbeing
Discuss the effects on confidence, social contact, sleep and everyday participation. Patient-reported quality of life belongs in treatment discussions alongside measured proptosis. [3]
Connect with informed peers
TED-specific groups offer shared experience and practical support. Their members may be at different stages or under different national treatment systems; peer advice does not replace clinical monitoring. [3]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
ATA/ETA TED consensus statement
Organizes care around activity, severity, specific functional problems and urgent sight-threatening disease. [3]
Limits and applicability: Guidance reflects evidence and access at publication, before newer chronic-disease trials and 2026 veligrotug approval. It does not replace individualized specialist judgment.
Teprotumumab in long-duration, low-activity TED
Met its proptosis primary endpoint at 24 weeks. Diplopia improvement was not significantly different in the small, uneven baseline diplopia subgroups. [7]
Limits and applicability: Excluded recent optic neuropathy and certain prior procedures; sponsor involvement and short post-treatment follow-up matter. This is not an emergency optic-neuropathy trial or proof of permanent benefit.
Veligrotug regulatory clinical evidence
Label reports improvements in proptosis and diplopia endpoints in the studied populations, supporting US approval regardless of activity or duration. [5] [6]
Limits and applicability: Placebo-controlled studies are not head-to-head comparisons with teprotumumab or surgery. Significant baseline ear pathology/hearing loss and IBD exclusions limit generalization; the current label carries important safety warnings.
Questions researchers still need to answer
- Which outcomes and baseline features best guide durable treatment choices across active and chronic disease?
- How do therapies compare directly on long-term visual function, hearing, quality of life, retreatment and accessibility?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
British Thyroid Foundation
Thyroid education and volunteer support, including an organization-listed closed TED Facebook group. The forum page explains how to request access; it is peer support, not medical advice.
Connections listed by the organization.
Thyroid Eye Disease Charitable Trust
TED-specific support team, patient information meetings, videos and a publicly linked UK community group. Confirm current meeting details; support discussions cannot assess threatened sight.
Connections listed by the organization.
The TED Community Organization
One-hour peer-facilitated Zoom conversations for TED and Graves disease, with optional camera use and published no-medical-advice/privacy guidelines. Registration is through the external organization; confirm upcoming dates.
Connections listed by the organization.
NANOS specialist directory
Search neuro-ophthalmology professionals. Listing does not guarantee an appointment, insurance coverage or emergency access.
National Eye Institute low-vision resources
Information on vision rehabilitation, accessible devices and task adaptations; ask locally about referral and service availability.
Questions you may still have
Can TED happen with normal thyroid levels?
Yes. Orbital disease and thyroid hormone status are related but distinct, so eye assessment remains important. [1]
Is all TED blur optic-nerve compression?
No. Surface exposure, misalignment and other causes can affect vision. New loss still needs assessment to identify the mechanism. [1] [2]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- NANOS — Thyroid Eye Disease (n.d.; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - National Eye Institute — Graves’ Eye Disease (n.d.; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - ATA/ETA — Management of thyroid eye disease: consensus statement (2022; guideline).
Public full consensus read; newer treatments considered separately. No claim it incorporates 2026 regulatory changes.
Checked 2026-10-24 · Full text checked - DailyMed — TEPEZZA prescribing information (2026; institution).
Current September 2026 label checked for indication and hearing, glucose, bowel, infusion and encephalopathy warnings; US scope only. Encephalopathy warning is teprotumumab-specific here, not assigned to veligrotug.
Checked 2026-10-24 · Public page checked - DailyMed — LUMVOA prescribing information (2026; institution).
June 29, 2026 label checked, including randomized study populations, exclusions and warnings. Regulatory clinical summary, not a head-to-head trial.
Checked 2026-10-24 · Public page checked - FDA — Lumvoa BLA 761530 approval package/letter (2026; institution).
Official PDF confirms June 26, 2026 approval; corroborated by FDA Purple Book BLA761530. No regulatory-review proposal confused with approval.
Checked 2026-10-24 · Public page checked - Efficacy and safety of teprotumumab in long-duration, low-activity TED (2024; trial).
Public full trial read; online 2023, journal issue 2024. Proptosis primary and nonsignificant diplopia subgroup kept distinct.
Checked 2026-10-24 · Full text checked - National Eye Institute — Low Vision (2025; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.